In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Amgen AMGN, but removed the $140.00 price target.
In the report, Morgan Stanley noted, “The AMAGINE-1 study is the 1st of three PhIII studies for brodalumab (AMAGINE-2 & 3 are head-to-head comparisons with Stelara). The two studied doses (210mg and 140mg) achieved statically significant PASI 75 (83.3% and 60.3% v 2.7%), PASI 90 (70.3% and 42.5% v 0.9%) and PASI 100 (41.9% and 28.7% v 0.5%) reductions vs placebo. Serious AEs were balanced (1.8% for 210mg, 2.7% for 140mg and 1.4% for pbo) with headaches and colds the most common AEs.”
Amgen closed on Friday at $111.48.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in